Illumina will collaborate with China’s KingMed Diagnostics to develop ready-to-use in-vitro diagnostic (IVD) assays for molecular oncology and hereditary cancer testing in China. The parties will combine Illumina’s bench-top MiniSeq NGS sequencer with KingMed’s testing components, which include library preparation kits and analysis software. In China, KingMed supplies testing products to 21,000 medical institutions and operates 37 independent testing labs.
Source: China Biotoday
